GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » PB Ratio

Phio Pharmaceuticals (Phio Pharmaceuticals) PB Ratio : 0.33 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Phio Pharmaceuticals's share price is $0.678. Phio Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $2.06. Hence, Phio Pharmaceuticals's PB Ratio of today is 0.33.

The historical rank and industry rank for Phio Pharmaceuticals's PB Ratio or its related term are showing as below:

PHIO' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1   Max: 32.18
Current: 0.33

During the past 13 years, Phio Pharmaceuticals's highest PB Ratio was 32.18. The lowest was 0.01. And the median was 1.00.

PHIO's PB Ratio is ranked better than
95.73% of 1311 companies
in the Biotechnology industry
Industry Median: 2.37 vs PHIO: 0.33

During the past 12 months, Phio Pharmaceuticals's average Book Value Per Share Growth Rate was -78.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -57.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -62.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -59.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Phio Pharmaceuticals was -38.60% per year. The lowest was -69.70% per year. And the median was -59.85% per year.

Back to Basics: PB Ratio


Phio Pharmaceuticals PB Ratio Historical Data

The historical data trend for Phio Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals PB Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.19 0.62 0.47 0.37

Phio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.88 0.58 0.48 0.37

Competitive Comparison of Phio Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Phio Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's PB Ratio falls into.



Phio Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Phio Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.678/2.063
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Phio Pharmaceuticals  (NAS:PHIO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Phio Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581

Phio Pharmaceuticals (Phio Pharmaceuticals) Headlines

From GuruFocus